The test has a complicated name: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. But the goal of the test, created by Fujirebio Diagnostics, is simple: Early detection of beta-amyloid plaques linked to the neurocognitive disease in adults 55 and older who are exhibiting signs and symptoms of the disorder.

The Lumipulse G Plasma Ratio Test offers a new way to detect signs of Alzheimer's disease by identifying plaque proteins in the blood. Dr. Celine Gounder joins to explain how this could make early diagnosis faster and more accessible.